Biofield Corp. On OTC Bulletin Board; Moves From 'Pink Sheets' Listing

Apr 20, 2001, 01:00 ET from Biofield Corp.

    ATLANTA, April 20 /PRNewswire Interactive News Release/ --
 Biofield Corp. (OTC Bulletin Board:   BZET) today announced that its common
 stock is now quoted on the OTC Bulletin Board.  As a result, commencing today,
 real-time quotations, price and volume information for Biofield again will be
 publicly available.
     Although Biofield had its initial public offering in March 1996, it
 terminated its reporting obligations to the SEC in March 1999.  Biofield
 resumed the filing of periodic reports with the SEC upon the effectiveness of
 its registration on Form 10-SB in October 2000, and timely filed its Annual
 Report for the year ended December 31, 2000 on Form 10-KSB.
     Dr. David M. Long, Jr., Chairman and CEO of Biofield, commented that
 "moving from the 'Pink Sheets' is the attainment of still another goal towards
 regaining our credibility.  Likewise, we were pleased that, earlier this week,
 the notified body KEMA advised us that it had continued CE Mark certification
 for our Biofield Diagnostic System."
     Biofield is a development stage medical device technology company that
 previously had developed a non-invasive system to assist in the detection of
 epithelial cancers, including breast cancer.  The Biofield Diagnostic System
 will require pre-market approval from the U.S. Food and Drug Administration
 before it can be made commercially available in the U.S.  Biofield anticipates
 submitting an application for such approval at a future date.
     Certain statements made in this press release should be considered
 forward-looking and subject to various risks and uncertainties.  Such forward-
 looking statements are based on management's belief as well as assumptions
 made by, and information currently available to, management pursuant to the
 "safe harbor" provisions of the Private Securities Litigation Reform Act of
 1995.  These forward looking statements can generally be identified as such
 because the context of the statement will include words such as "believes,"
 "anticipates," "expects," "promising," "preliminary" or words of similar
 import.  Similarly, statements that describe the Company's future plans,
 objectives, estimates or goals are also forward-looking statements.  Such
 statements may address future events and conditions concerning, among other
 matters FDA acceptance of the Company's application for PMA approval, which
 application has not yet been submitted, and the granting of PMA approval by
 the FDA, which may not occur or, if it does, may not be timely.  Additional
 factors which should be considered are set forth in the Company's registration
 statement on Form 10-SB and its Annual Report on Form 10-KSB for its fiscal
 year ended December 31, 2000.  Copies of such documents are obtainable from
 the EDGAR database internet web site maintained by the Securities and Exchange
 Commission at http:/www.sec.gov/edgarhp.htm .  The Company undertakes no
 obligation to release publicly the results of any revisions to its forward-
 looking statements that may be made in this press release to reflect events or
 circumstances occurring after the date of this press release or to reflect the
 occurrence of other unanticipated events.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X48284456
 
 

SOURCE Biofield Corp.
    ATLANTA, April 20 /PRNewswire Interactive News Release/ --
 Biofield Corp. (OTC Bulletin Board:   BZET) today announced that its common
 stock is now quoted on the OTC Bulletin Board.  As a result, commencing today,
 real-time quotations, price and volume information for Biofield again will be
 publicly available.
     Although Biofield had its initial public offering in March 1996, it
 terminated its reporting obligations to the SEC in March 1999.  Biofield
 resumed the filing of periodic reports with the SEC upon the effectiveness of
 its registration on Form 10-SB in October 2000, and timely filed its Annual
 Report for the year ended December 31, 2000 on Form 10-KSB.
     Dr. David M. Long, Jr., Chairman and CEO of Biofield, commented that
 "moving from the 'Pink Sheets' is the attainment of still another goal towards
 regaining our credibility.  Likewise, we were pleased that, earlier this week,
 the notified body KEMA advised us that it had continued CE Mark certification
 for our Biofield Diagnostic System."
     Biofield is a development stage medical device technology company that
 previously had developed a non-invasive system to assist in the detection of
 epithelial cancers, including breast cancer.  The Biofield Diagnostic System
 will require pre-market approval from the U.S. Food and Drug Administration
 before it can be made commercially available in the U.S.  Biofield anticipates
 submitting an application for such approval at a future date.
     Certain statements made in this press release should be considered
 forward-looking and subject to various risks and uncertainties.  Such forward-
 looking statements are based on management's belief as well as assumptions
 made by, and information currently available to, management pursuant to the
 "safe harbor" provisions of the Private Securities Litigation Reform Act of
 1995.  These forward looking statements can generally be identified as such
 because the context of the statement will include words such as "believes,"
 "anticipates," "expects," "promising," "preliminary" or words of similar
 import.  Similarly, statements that describe the Company's future plans,
 objectives, estimates or goals are also forward-looking statements.  Such
 statements may address future events and conditions concerning, among other
 matters FDA acceptance of the Company's application for PMA approval, which
 application has not yet been submitted, and the granting of PMA approval by
 the FDA, which may not occur or, if it does, may not be timely.  Additional
 factors which should be considered are set forth in the Company's registration
 statement on Form 10-SB and its Annual Report on Form 10-KSB for its fiscal
 year ended December 31, 2000.  Copies of such documents are obtainable from
 the EDGAR database internet web site maintained by the Securities and Exchange
 Commission at http:/www.sec.gov/edgarhp.htm .  The Company undertakes no
 obligation to release publicly the results of any revisions to its forward-
 looking statements that may be made in this press release to reflect events or
 circumstances occurring after the date of this press release or to reflect the
 occurrence of other unanticipated events.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X48284456
 
 SOURCE  Biofield Corp.